PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
WEBOptimizing Patient Recruitment & Retention in Influenza Studies. Aug 16, 2024 Webinars. With the flu season rapidly approaching, there is a surge in influenza and vaccine-related studies. These studies often face the significant challenge of a very short recruitment window, which necessitates thorough preparation and strategic planning during ...
Roche’s injectable Ocrevus Zunovo granted FDA approval to treat ...
WEB5 days ago · Roche’s injectable monoclonal antibody Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) has been approved by the US Food and Drug Administration (FDA) to treat both relapsing and primary progressive multiple sclerosis (MS). The subcutaneous (SC) formulation, which combines Ocrevus (ocrelizumab) with Halozyme Therapeutics’ Enhanze drug ...
Pfizer and BioNTech share late-stage results for COVID-19/flu ...
WEBAug 16, 2024 · Pfizer and BioNTech have announced top-line results from a late-stage study of their mRNA-based combination vaccine for influenza and COVID-19. The partners have been evaluating the candidate against a licensed flu vaccine and their own licensed COVID-19 vaccine given at the same visit in more …
PME - Articles - Pharmaceutical Market Europe
WEBNews - July/Aug 2024. Roche and Ascidian agree to $1.8bn neurological disease partnership. 15 July 2024 News & Columns. Read More. Dermatology news - July/Aug 2024. UCB’s Bimzelx approved by MHRA for hidradenitis suppurativa. 15 July 2024 News & Columns. Read More. DARWIN'S MEDICINE - Bayer's octopus move.
Sanofi/Regeneron’s Dupixent receives FDA approval for …
WEB5 days ago · Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for adolescents with chronic rhinosinusitis with nasal polyps (CRSwNP). The regulator’s decision, which expands its previous approval of the drug in CRSwNP patients aged 18 years and older ...
PME - Home
WEBHow AI and digital innovations can help agencies and pharma support HCPs in the fight against COVID-19 - PME Supplement August 2020. As the realities of COVID-19 hit and lockdown restrictions came into force around the world, agencies and pharma suddenly found themselves embracing AI and digital innovations at an accelerated rate.
Regulatory - PMLiVE
WEBSep 17, 2024 | News, Regulatory. Approximately 9,000 adolescents in the US are living with inadequately controlled cases of the chronic disease. Read More.
Sales - PMLiVE
WEBEli Lilly and Genetic Leap partner to develop RNA-targeted therapies in deal worth $409m. Sep 10, 2024 | News, Sales. The companies will use Genetic Leap’s AI platform to generate oligonucleotide drugs against targets selected by Lilly. Read More.
Johnson & Johnson's IL-23 inhibitor Tremfya granted FDA …
WEBSep 12, 2024 · Johnson & Johnson’s (J&J) dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderately to severely active ulcerative colitis (UC). Estimated to affect more than one million people in the US, UC is a type of inflammatory bowel disease (IBD) that causes ...
Healthcare Archives - PMLiVE
WEBJCVI announces advice for autumn COVID-19 vaccination programme eligibility. Aug 6, 2024 | News, Healthcare. The Committee has advised offering the vaccine to those at high risk of serious disease. Read More.
Skip to content